Chittal Abhinandan R, Rao Shiavax J, Lakra Pallavi, Zulty Mary E
Department of Medicine, MedStar Health Internal Medicine Residency Program, Baltimore, MD, USA.
J Community Hosp Intern Med Perspect. 2021 Nov 15;11(6):779-781. doi: 10.1080/20009666.2021.1979738. eCollection 2021.
COVID-19, also known as SARS-CoV-2, which originated in China in late 2019, has spread rapidly resulting in a global pandemic. COVID-19 has been linked to many different clinical manifestations, including hyponatremia. The cause of hyponatremia in acute COVID-19 infection is speculated to be multifactorial, including syndrome of inappropriate antidiuretic hormone secretion (SIADH), thought to be a result of inflammatory cytokines (Interleukin-6) and/or related to the gastrointestinal symptoms of this infection. SIADH in the setting of COVID-19 pneumonia is an established complication of this disease. This is the case of an 81-year-old woman with a history of hypertension, on thiazide diuretic, initially presented after a fall in the setting of COVID-19 pneumonia. She was treated with remdesivir and dexamethasone and then discharged to a rehab facility with normal labwork, including a sodium of 137 mmol/L. Two weeks later, routine labwork identified hyponatremia of 111 mmol/L. Her vital signs were normal, she was euvolemic on exam and alert/oriented with no complaints. Investigations into the etiology of her hyponatremia included a urine sodium of 72 mmol/L, serum osmolality of 231 mOsm/kg, urine osmolality of 454 mOsm/kg. We diagnosed hypo-osmolar hyponatremia due to SIADH. Management included fluid restriction and then tolvaptan, which ultimately corrected the serum sodium to 134 mmol/L. As COVID-19 is a new infection, little is known regarding its impact on electrolyte imbalances. Our patient recovered from pneumonia, then later developed severe hyponatremia possibly secondary to the lasting effects of inflammation in her lungs.
2019年末起源于中国的新型冠状病毒肺炎(COVID-19,又称严重急性呼吸综合征冠状病毒2)迅速传播,导致全球大流行。COVID-19与许多不同的临床表现有关,包括低钠血症。急性COVID-19感染时低钠血症的病因推测是多因素的,包括抗利尿激素分泌不当综合征(SIADH),这被认为是炎性细胞因子(白细胞介素-6)的结果和/或与该感染的胃肠道症状有关。COVID-19肺炎患者出现SIADH是该疾病的一种既定并发症。本文报告了一例81岁女性,有高血压病史,正在服用噻嗪类利尿剂,最初因COVID-19肺炎跌倒后就诊。她接受了瑞德西韦和地塞米松治疗,然后出院到康复机构,实验室检查结果正常,包括血钠为137 mmol/L。两周后,常规实验室检查发现血钠为111 mmol/L的低钠血症。她的生命体征正常,体格检查时血容量正常,意识清醒/定向正常,无不适主诉。对其低钠血症病因的检查包括尿钠72 mmol/L、血清渗透压231 mOsm/kg、尿渗透压454 mOsm/kg。我们诊断为SIADH所致的低渗性低钠血症。治疗包括限液,然后使用托伐普坦,最终将血钠纠正至134 mmol/L。由于COVID-19是一种新出现的感染,关于其对电解质失衡的影响知之甚少。我们的患者肺炎康复后,后来出现严重低钠血症,可能继发于肺部炎症的持续影响。